Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATO-101 in BCG-unresponsive Non-Muscle-Invasive Bladder Cancer
NCT07260162Phase 1Not yet recruiting
- Sponsor
- Institut Cancérologique de l'Ouest
- Start
- Jan 2027
- Primary completion
- Jan 2029
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of [211At]At-girentuximab in non-muscle-invasive bladder cancer (NMIBC), sponsored by Institut Cancérologique de l'Ouest. Primary endpoints: Maximum Tolerated Dose at 15 days and Recommended Dose for Expansion at 15 days. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
[211At]At-girentuximab
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT07260162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07260162.